FDA Approves Cobenfy: First Novel Schizophrenia Drug in Decades
The Food and Drug Administration (FDA) has approved Cobenfy, marking the first novel antipsychotic treatment for schizophrenia in decades. This innovative drug offers a new approach to managing the condition, aiming to reduce disabling side effects, particularly weight gain, which is common with existing antipsychotic treatments.
Traditionally, antipsychotics have operated